156 related articles for article (PubMed ID: 38142919)
1. Dietary fibre confers therapeutic effects in a preclinical model of Huntington's disease.
Gubert C; Kong G; Costello C; Adams CD; Masson BA; Qin W; Choo J; Narayana VK; Rogers G; Renoir T; Furness JB; Hannan AJ
Brain Behav Immun; 2024 Feb; 116():404-418. PubMed ID: 38142919
[TBL] [Abstract][Full Text] [Related]
2. Microbiome profiling reveals gut dysbiosis in a transgenic mouse model of Huntington's disease.
Kong G; Cao KL; Judd LM; Li S; Renoir T; Hannan AJ
Neurobiol Dis; 2020 Feb; 135():104268. PubMed ID: 30194046
[TBL] [Abstract][Full Text] [Related]
3. Alterations in the Gut Fungal Community in a Mouse Model of Huntington's Disease.
Kong G; Lê Cao KA; Hannan AJ
Microbiol Spectr; 2022 Apr; 10(2):e0219221. PubMed ID: 35262396
[TBL] [Abstract][Full Text] [Related]
4. An integrated metagenomics and metabolomics approach implicates the microbiota-gut-brain axis in the pathogenesis of Huntington's disease.
Kong G; Ellul S; Narayana VK; Kanojia K; Ha HTT; Li S; Renoir T; Cao KL; Hannan AJ
Neurobiol Dis; 2021 Jan; 148():105199. PubMed ID: 33249136
[TBL] [Abstract][Full Text] [Related]
5. Faecal microbiota transplant ameliorates gut dysbiosis and cognitive deficits in Huntington's disease mice.
Gubert C; Choo JM; Love CJ; Kodikara S; Masson BA; Liew JJM; Wang Y; Kong G; Narayana VK; Renoir T; Lê Cao KA; Rogers GB; Hannan AJ
Brain Commun; 2022; 4(4):fcac205. PubMed ID: 36035436
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Effects of Anthocyanins and Environmental Enrichment in R6/1 Huntington's Disease Mice.
Kreilaus F; Spiro AS; Hannan AJ; Garner B; Jenner AM
J Huntingtons Dis; 2016 Oct; 5(3):285-296. PubMed ID: 27567888
[TBL] [Abstract][Full Text] [Related]
7. Hypothalamic expression of huntingtin causes distinct metabolic changes in Huntington's disease mice.
Dickson E; Soylu-Kucharz R; Petersén Å; Björkqvist M
Mol Metab; 2022 Mar; 57():101439. PubMed ID: 35007790
[TBL] [Abstract][Full Text] [Related]
8. A selective inhibitor of the NLRP3 inflammasome as a potential therapeutic approach for neuroprotection in a transgenic mouse model of Huntington's disease.
Chen KP; Hua KF; Tsai FT; Lin TY; Cheng CY; Yang DI; Hsu HT; Ju TC
J Neuroinflammation; 2022 Feb; 19(1):56. PubMed ID: 35219323
[TBL] [Abstract][Full Text] [Related]
9. Corticosterone dysregulation exacerbates disease progression in the R6/2 transgenic mouse model of Huntington's disease.
Dufour BD; McBride JL
Exp Neurol; 2016 Sep; 283(Pt A):308-17. PubMed ID: 27381424
[TBL] [Abstract][Full Text] [Related]
10. Gut dysbiosis in Huntington's disease: associations among gut microbiota, cognitive performance and clinical outcomes.
Wasser CI; Mercieca EC; Kong G; Hannan AJ; McKeown SJ; Glikmann-Johnston Y; Stout JC
Brain Commun; 2020; 2(2):fcaa110. PubMed ID: 33005892
[TBL] [Abstract][Full Text] [Related]
11. Exercise attenuates neuropathology and has greater benefit on cognitive than motor deficits in the R6/1 Huntington's disease mouse model.
Harrison DJ; Busse M; Openshaw R; Rosser AE; Dunnett SB; Brooks SP
Exp Neurol; 2013 Oct; 248():457-69. PubMed ID: 23911978
[TBL] [Abstract][Full Text] [Related]
12. The influence of the HPG axis on stress response and depressive-like behaviour in a transgenic mouse model of Huntington's disease.
Du X; Pang TY; Mo C; Renoir T; Wright DJ; Hannan AJ
Exp Neurol; 2015 Jan; 263():63-71. PubMed ID: 25246229
[TBL] [Abstract][Full Text] [Related]
13. Effects of chronic stress on the onset and progression of Huntington's disease in transgenic mice.
Mo C; Renoir T; Hannan AJ
Neurobiol Dis; 2014 Nov; 71():81-94. PubMed ID: 25088714
[TBL] [Abstract][Full Text] [Related]
14. Gut microbiota dysbiosis and Huntington's disease: Exploring the gut-brain axis and novel microbiota-based interventions.
Sharma G; Biswas SS; Mishra J; Navik U; Kandimalla R; Reddy PH; Bhatti GK; Bhatti JS
Life Sci; 2023 Sep; 328():121882. PubMed ID: 37356750
[TBL] [Abstract][Full Text] [Related]
15. An independent study of the preclinical efficacy of C2-8 in the R6/2 transgenic mouse model of Huntington's disease.
Wang N; Lu XH; Sandoval SV; Yang XW
J Huntingtons Dis; 2013; 2(4):443-51. PubMed ID: 25062731
[TBL] [Abstract][Full Text] [Related]
16. N-Acetylcysteine improves mitochondrial function and ameliorates behavioral deficits in the R6/1 mouse model of Huntington's disease.
Wright DJ; Renoir T; Smith ZM; Frazier AE; Francis PS; Thorburn DR; McGee SL; Hannan AJ; Gray LJ
Transl Psychiatry; 2015 Jan; 5(1):e492. PubMed ID: 25562842
[TBL] [Abstract][Full Text] [Related]
17. Normalizing glucocorticoid levels attenuates metabolic and neuropathological symptoms in the R6/2 mouse model of huntington's disease.
Dufour BD; McBride JL
Neurobiol Dis; 2019 Jan; 121():214-229. PubMed ID: 30292559
[TBL] [Abstract][Full Text] [Related]
18. Downregulation of glial genes involved in synaptic function mitigates Huntington's disease pathogenesis.
Onur TS; Laitman A; Zhao H; Keyho R; Kim H; Wang J; Mair M; Wang H; Li L; Perez A; de Haro M; Wan YW; Allen G; Lu B; Al-Ramahi I; Liu Z; Botas J
Elife; 2021 Apr; 10():. PubMed ID: 33871358
[TBL] [Abstract][Full Text] [Related]
19. The microbiota-gut-brain axis in Huntington's disease.
Love CJ; Masson BA; Gubert C; Hannan AJ
Int Rev Neurobiol; 2022; 167():141-184. PubMed ID: 36427954
[TBL] [Abstract][Full Text] [Related]
20. Microglial physiological properties and interactions with synapses are altered at presymptomatic stages in a mouse model of Huntington's disease pathology.
Savage JC; St-Pierre MK; Carrier M; El Hajj H; Novak SW; Sanchez MG; Cicchetti F; Tremblay MÈ
J Neuroinflammation; 2020 Apr; 17(1):98. PubMed ID: 32241286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
